Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma
Authors:
- Hiroshi AikataHAHiroshi Aikata
- Yoshio KatamuraYKYoshio Katamura
- Takahiro AzakamiTATakahiro Azakami
- Tomokazu KawaokaTKTomokazu Kawaoka
- Hiromi SanetoHSHiromi Saneto
- Kiminori UkaKUKiminori Uka
- Nami MoriNMNami Mori
- Shintaro TakakiSTShintaro Takaki
- Hideaki KodamaHKHideaki Kodama
- Koji WakiKWKoji Waki
- Michio ImamuraMIMichio Imamura
- 1 January 2007
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 13 (39) , 5188-95
Abstract
To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN-alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group). The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not significant, the score was significantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 +/- 1.42 vs 5.81 +/- 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrent HCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively). Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation.Keywords
This publication has 36 references indexed in Scilit:
- Management of cirrhosis due to chronic hepatitis CJournal of Hepatology, 2005
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumorsCancer, 2004
- Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C VirusAnnals of Internal Medicine, 2003
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998
- Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver DiseaseNew England Journal of Medicine, 1993
- Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinomaCancer, 1993
- Long–Term Follow–Up of Patients With Chronic Hepatitis C Treated With α–InterferonHepatology, 1992
- Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-αHepatology, 1992
- Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.1991